SCHEMBL26067691

SCHEMBL26067691

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OC3[C@@H](COP(=O)(O)O)O[C@@H](n4cnc5c(N)ncnc54)[C@H]3F)C(O)[C@@H]2O)c(=O)[nH]1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNASEL Q05823 12/20 0.71
▸ DNPH1 O43598 1/20 0.65
▸ PRKAB2 O43741 1/20 0.65
▸ TRPM2 O94759 1/20 0.65
▸ LDHA P00338 1/20 0.65
▸ ADRB2 P07550 1/20 0.65
▸ FBP1 P09467 1/20 0.65
▸ SRC P12931 1/20 0.65
▸ ADORA1 P30542 1/20 0.65
▸ P2RY2 P41231 1/20 0.65
▸ P2RY1 P47900 1/20 0.65
▸ PRKAG1 P54619 1/20 0.65
▸ PRKAA2 P54646 1/20 0.65
▸ PDE4D Q08499 1/20 0.65
▸ KCNH2 Q12809 1/20 0.65
▸ PRKAA1 Q13131 1/20 0.65
▸ PDE3A Q14432 1/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.65
▸ TAS1R3 Q7RTX0 1/20 0.65
▸ TAS1R1 Q7RTX1 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25400954 1.00 RNASEL (0.71) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL26067746 1.00 RNASEL (0.71) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL26067741 0.96 RNASEL (0.65) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL21516054 0.96 RNASEL (0.66) RNASELSRCP2RY2P2RY1SMN1; SMN2
SCHEMBL21516052 0.96 RNASEL (0.66) RNASELSRCP2RY2P2RY1SMN1; SMN2
SCHEMBL26579029 0.95 RNASEL (0.72) RNASELTRPM2SRCP2RY2P2RY1
SCHEMBL9951563 0.95 RNASEL (0.76) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL30084833 0.95 RNASEL (0.76) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL26067589 0.94 RNASEL (0.62) RNASELSRCP2RY2P2RY1SMN1; SMN2
SCHEMBL26067573 0.94 RNASEL (0.62) RNASELSRCP2RY2P2RY1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250127-A1 MODIFIED mRNA 5'-CAP ANALOGS Nanjing GeneLeap Biotechnology Co., Ltd. (CN) 2023-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250127-A1 MODIFIED mRNA 5'-CAP ANALOGS RNGTT, RNMT, NSUN2 RNASEL 96/4885DNPH1 639/4885PRKAB2 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback